Which clinical-stage biotech stock wins in a head-to-head match-up between Agenus and Alnylam?
Data from a competitor gives investors hope that the company's drug will have a larger potential market.
Bargain-hunters can start off the year by taking a deeper look at these three promising healthcare stocks.
Looking for cheap biotech stocks you can buy now? These three may be bargains.
The Soros Fund showed a healthy appetite for biotech stocks in Q3 -- ignoring the political risk.
The Fidelity Select Health Care Fund is a top healthcare fund thanks to bold bets on its favorite stock picks.
Here's why Amgen, Gilead Sciences, and Lilly just might have paid a lower effective tax rate than you did in 2015.
Poor Q3 results combined with allegations of submitting claims for deceased patients equals a bad day.
Here's what you need to know about what Amgen's management said in the biotech's Q3 earnings call.
Market potential for Nuplazid and a lower market cap could make ACADIA a prime acquisition target.